scholarly article | Q13442814 |
P50 | author | Tsukasa Ohmori | Q73012013 |
P2093 | author name string | Shuji Hishikawa | |
Keiya Ozawa | |||
Yoichi Sakata | |||
Hiroaki Mizukami | |||
Akira Ishiwata | |||
Jun Mimuro | |||
Seiji Madoiwa | |||
Fumiko Ono | |||
Tomokazu Ikemoto | |||
Asuka Sakata | |||
P2860 | cites work | Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. | Q45859498 |
Update on progress and hurdles in novel genetic therapies for hemophilia | Q45872938 | ||
Specific detection of human coagulation factor IX in cynomolgus macaques | Q45873385 | ||
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. | Q45882349 | ||
Hepatic venous compliance and role of liver as a blood reservoir | Q46441130 | ||
Calculation of child and adult standard liver volume for liver transplantation. | Q52342275 | ||
Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized cats | Q54487623 | ||
Gene therapy for the hemophilias | Q64377524 | ||
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 | ||
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
AAV-mediated liver-directed gene therapy. | Q33987462 | ||
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity | Q34069571 | ||
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
The hemophilias--from royal genes to gene therapy | Q34276237 | ||
Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line | Q34327402 | ||
Gene therapy for haemophilia. | Q34530130 | ||
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. | Q34994506 | ||
A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates. | Q34994549 | ||
Adeno-associated virus antibody profiles in newborns, children, and adolescents | Q35191112 | ||
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates | Q35628868 | ||
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
Clinical gene transfer studies for hemophilia A. | Q35760801 | ||
Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver | Q35848563 | ||
Preclinical and clinical gene therapy for haemophilia | Q35915704 | ||
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects | Q37146095 | ||
Immune responses to AAV in clinical trials | Q37873955 | ||
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia | Q39519818 | ||
Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
Conceptual review of the hepatic vascular bed. | Q39669839 | ||
Cardiorespiratory effects of rapid saline infusion in normal man | Q40316981 | ||
Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy | Q41579770 | ||
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors | Q44258968 | ||
Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques | Q45731350 | ||
Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques. | Q45857121 | ||
P433 | issue | 2 | |
P921 | main subject | vector-borne disease | Q2083837 |
P304 | page(s) | 318-323 | |
P577 | publication date | 2012-12-18 | |
P1433 | published in | Molecular Therapy | Q15762400 |
P1476 | title | Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors | |
P478 | volume | 21 |
Q36713767 | Adeno-associated viral vectors for the treatment of hemophilia. |
Q57170592 | Advances in gene therapy for hemophilia: basis, current status, and future perspectives |
Q33830117 | CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. |
Q27014770 | Cardiovascular gene therapy for myocardial infarction |
Q42271911 | Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors |
Q38206852 | Current status of haemophilia gene therapy |
Q30152887 | Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer |
Q47554736 | Emerging Issues in AAV-Mediated In Vivo Gene Therapy |
Q41171011 | Flushing out antibodies to make AAV gene therapy available to more patients |
Q99579530 | Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century |
Q28081911 | Gene therapy for hemophilia |
Q57167448 | Gene therapy for hemophilia: what does the future hold? |
Q64246797 | Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency |
Q37310450 | Gene therapy to treat cardiovascular disease |
Q37236099 | Humoral Immune Response to AAV. |
Q92863312 | Immune Response Mechanisms against AAV Vectors in Animal Models |
Q36983740 | Immune responses to AAV vectors: overcoming barriers to successful gene therapy |
Q90000829 | Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates |
Q33924645 | Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo |
Q38543280 | New approaches to gene and cell therapy for hemophilia. |
Q38529941 | Obstacles and future of gene therapy for hemophilia |
Q42056009 | Overcoming preexisting humoral immunity to AAV using capsid decoys |
Q38191212 | Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors |
Q38684383 | Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity |
Q36398678 | Strategies to circumvent humoral immunity to adeno-associated viral vectors |
Q33902499 | The potential of adeno-associated viral vectors for gene delivery to muscle tissue |
Q42261520 | The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals |
Q40073271 | Unraveling the complex story of immune responses to AAV vectors trial after trial |
Q89748411 | Utility of microminipigs for evaluating liver-mediated gene expression in the presence of neutralizing antibody against vector capsid |
Search more.